CLPT
ClearPoint Neuro, Inc.
CLPT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
CLPT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
CLPT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CLPT PE Valuation
CLPT has no meaningful PE right now: it lost money over the past year.
CLPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CLPT's losses to shrink, with revenue growing.
CLPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.20 | -$0.36 |
| Q2 2026 | -$1.17 | -$0.36 |
| Q1 2026 | -$1.00 | -$0.24 |
| Q4 2025 | -$0.90 | -$0.20 |
| Q3 2025 | -$0.84 | -$0.16 |
| Q2 2025 | -$0.81 | -$0.11 |
| Q1 2025 | -$0.76 | +$0.07 |
| Q4 2024 | -$0.70 | +$0.20 |
CLPT lost $1.20 per share over the past year, a bigger loss than the year before.
CLPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.1M | +36% |
| Q2 2026 | $10.9M | +18% |
| Q1 2026 | $12.1M | +43% |
| Q4 2025 | $10.4M | +34% |
| Q3 2025 | $8.9M | +9.1% |
| Q2 2025 | $9.2M | +17% |
| Q1 2025 | $8.5M | +11% |
| Q4 2024 | $7.8M | +14% |
CLPT's revenue has grown year over year every quarter since late 2020: $12M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -52% | +7.1 points |
| Q2 2026 | -94% | -33 points |
| Q1 2026 | -70% | +2.7 points |
| Q4 2025 | -68% | +4.4 points |
| Q3 2025 | -60% | +4.1 points |
| Q2 2025 | -62% | -1.3 points |
| Q1 2025 | -73% | -17 points |
| Q4 2024 | -72% | -3 points |
CLPT's operating margin was −52% last quarter, up 7.1 points from the same quarter a year ago.
CLPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | -$16.9M |
| Q2 2026 | -$7.2M | -$4.6M |
| Q1 2026 | -$8.6M | -$2.3M |
| Q4 2025 | -$12.1M | -$10.6M |
| Q3 2025 | -$3.3M | -$2.1M |
| Q2 2025 | -$2.6M | +$25K |
| Q1 2025 | -$6.4M | -$2.5M |
| Q4 2024 | -$1.5M | -$316K |
CLPT has burned cash in almost every quarter: −$48M over the past year, against −$14M the year before.
CLPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +817K shares |
| 1 year | +9% | +2.6M shares |
| 3 years | +26% | +6.4M shares |
| 5 years | +38% | +8.5M shares |
| Available history | +136% | +17.8M shares |
CLPT has 31M diluted shares, up 9% from a year ago.
CLPT Net Leverage
CLPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 9.1 | Oversold |
CLPT's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
CLPT PE vs Healthcare Sector
CLPT has no meaningful PE right now: it lost money over the past year.
CLPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 17% below |
| 20 week MA | $13.2 | 36% below |
| 50 week MA | $13.0 | 34% below |
| 100 week MA | $13.8 | 39% below |
| 200 week MA | $10.8 | 22% below |
CLPT is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
CLPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $13.8 | +175% |
| 2021 | $13.8 | $11.8 | -15% |
| 2022 | $11.8 | $7.96 | -32% |
| 2023 | $7.96 | $6.79 | -15% |
| 2024 | $6.79 | $15.8 | +132% |
| 2025 | $15.8 | $14.0 | -11% |
| 2026 YTD | $14.0 | $8.49 | -39% |
CLPT has finished lower in four of the last six years. It's down 39% so far in 2026.